Evolv Technologies Holdings, Inc. (EVLV) SEC Filings

Michael Ellenbogen, Founder and Chief Innovation Officer of Evolv Technologies Holdings, Inc. (EVLV), reported transactions on 09/15/2025. He exercised 80,745 stock options with a $0.24 exercise price, resulting in acquisition of 80,745 Class A shares. On the same date he sold 80,745 Class A shares under a Rule 10b5-1 plan at a weighted average price of $8.46 per share (individual sale prices ranged $8.34–$8.80). Following the transactions, he reported 2,083,961 Class A shares held directly and 151,135 held indirectly by the Family Horizon Trust. The option expires 09/13/2027 and vested 25% on 01/31/2018 with subsequent monthly vesting; the Form 4 was signed by an attorney-in-fact on 09/17/2025.

Evolv Technologies Holdings, Inc. (EVLV) submitted a Form 144 disclosing a proposed sale of 242,235 Class A common shares through J.P. Morgan Securities LLC on 09/15/2025 on Nasdaq with an aggregate market value of $2,124,401. The filing shows these shares were acquired and paid for on 09/15/2025 via a stock option exercise and payment in cash. The filer reports 171,891,467 shares outstanding and states there were no sales in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Mark J. Sullivan, a director of Evolv Technologies Holdings, Inc. (EVLV), reported the vesting and issuance of 26,388 restricted stock units (RSUs) on September 2, 2025. Each RSU converts into one share of Class A common stock and vested in full on that date at no purchase price, increasing his beneficial ownership to 208,003 shares. The RSUs have no expiration date. The Form 4 was signed by an attorney-in-fact on September 3, 2025. All information is limited to the transactions and holdings disclosed on the form.

Data Collective IV, L.P. ("DC IV") and related reporting persons report beneficial ownership of 8,096,335 shares of Evolv Technologies Holdings, Inc. Class A Common Stock, representing 4.7% of the 171,891,467 shares outstanding used to calculate the percentage. The shares held by DC IV resulted from prior preferred-stock and convertible-note investments in Old Evolv that converted into issuer common stock in connection with the business combination described in the filing.

The filing discloses multiple open-market sales by DC IV, including sales on August 11–18, 2025 totaling 1,584,946 shares for aggregate reported proceeds of approximately $12,357,398.50. The reporting persons state the securities are held for general investment purposes and that they may buy or sell depending on market and other conditions. The filing also references the Registration Rights Agreement that governs resale and lock-up arrangements following the business combination.

Evolv Technologies Holdings reported that Stoic Point Capital Management and two individuals may beneficially own 5,396,901 shares of the issuer's Class A common stock, representing 3.1% of the outstanding Class A shares based on 171,891,467 shares outstanding. The reporting persons state the position cost approximately $13,847,006 and was funded from the working capital of private funds and separately managed accounts they manage. The holdings break down as 1,708,495 shares held by funds and 3,688,406 shares held by SMAs. The filing notes no other transactions in the past sixty days except as listed on an attached schedule.

Evolv Technologies (EVLV) reported a quarter marked by accounting restatements, ongoing legal and regulatory matters, and continued operating losses despite product launches and financing. The company restated prior-period condensed consolidated financial statements after an internal investigation found extra-contractual terms that affected revenue recognition and led to personnel changes. Evolv had $36.9 million in cash, cash equivalents, and marketable securities as of June 30, 2025, and expects that, together with expected cash from operations and borrowing availability under newly negotiated Senior Secured Credit Facilities, it has at least twelve months of liquidity. The company recorded a net loss of $42.2 million for the six months ended June 30, 2025, recognized restructuring charges related to a reduction in force, and disclosed material weaknesses in internal controls with an active remediation plan. Significant contingencies include shareholder class and derivative actions, FTC and SEC matters, and an estimated $15.0 million settlement accrual for the class action with an expected $14.0 million insurance recovery.

Evolv Technologies Holdings, Inc. filed a current report describing two developments. The company announced that it released its financial results for the fiscal quarter ended June 30, 2025, with the full details provided in a separate press release furnished as an exhibit.

The company also reported that Michael Ellenbogen, its Chief Innovation Officer and a member of the Board of Directors, informed the company on August 13, 2025 that he will resign from his Chief Innovation Officer role effective September 5, 2025, citing new time commitments. His decision is stated to be not due to any disagreements with the company. He will continue to serve as a member of the Board and will receive compensation as a non-employee director under the company’s director compensation policy.